Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology

What problem does this paper attempt to address?

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Xia Li,Xiufeng Yin,Huafeng Wang,Jiansong Huang,Mengxia Yu,Zhixin Ma,Chenying Li,Yile Zhou,Xiao Yan,ShuJuan Huang,Jie Jin

DOI: https://doi.org/10.18632/oncotarget.27310

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14463.].
Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Jiaojiao Hao,Zhenglin Li,Changlin Zhang,Wendan Yu,Zhipeng Tang,Yixin Li,Xu Feng,Yue Gao,Quentin Liu,Wenlin Huang,Wei Guo,Wuguo Deng

DOI: https://doi.org/10.62347/suki5933

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 13 in vol. 7, PMID: 28123844.].
Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Yihui Zhou,Xiaomeng Gao,Yuan Meng,Bo Yang,Qiaojun He,Ji Cao

DOI: https://doi.org/10.3389/fphar.2021.785732

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2021.748852.].
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Xuan Wei,Juanjuan Shi,Qianhan Lin,Xiaoxue Ma,Yingxin Pang,Hongluan Mao,Rui Li,Wei Lu,Yu Wang,Peishu Liu

DOI: https://doi.org/10.3389/fonc.2021.742374

IF: 4.7

2021-09-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.642229.].

oncology
Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Qi Chang Zheng,Shuai Jiang,Yu Zhe Wu,Dan Shang,Yong Zhang,Shao Bo Hu,Xiang Cheng,Chen Zhang,Ping Sun,Yang Gao,Zi Fang Song,Min Li

DOI: https://doi.org/10.3389/fbioe.2021.656268

IF: 5.7

2021-02-11

Frontiers in Bioengineering and Biotechnology

Abstract:[This corrects the article DOI: 10.3389/fbioe.2020.00512.].

multidisciplinary sciences
Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Hongzhi Li,Weihua Yuan,Shufang Bin,Guang Wu,Panyuan Li,Min Liu,Jifeng Yang,Xiang Li,Kaiyan Yang,Haihua Gu

2022-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 688 in vol. 10, PMID: 32195036.].
Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Jun Cao,Mengdi Zhang,Bin Wang,Long Zhang,Fangfang Zhou,Meiyu Fang

DOI: https://doi.org/10.3389/fonc.2021.745052

IF: 4.7

2021-08-17

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.658552.].

oncology
Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Haibo Xing,Mengting Tong,Jing Wang,Hanqing Hu,Chongya Zhai,Chunhui Huang,Da Li

DOI: https://doi.org/10.1155/2022/9767389

2022-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2018/3195025.].
Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Wei Wang,Bo Hu,Jiang-Jiang Qin,Jianwen Cheng,Xin Li,Mehrdad Rajaei,Jia Fan,Xin-Rong Yang,Ruiwen Zhang

DOI: https://doi.org/10.1016/j.gendis.2019.12.006

IF: 7.376

2019-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2019.06.001.].
Correction: Targeting Tumor Cell-Derived CCL2 As a Strategy to Overcome Bevacizumab Resistance in ETV5+ Colorectal Cancer.

Haoran Feng,Kun Liu,Xiaonan Shen,Juyong Liang,Changgang Wang,Weihua Qiu,Xi Cheng,Ren Zhao

DOI: https://doi.org/10.1038/s41419-020-03208-z

2020-01-01

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41419-020-03208-z.
Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Xin Tian,Lina Wu,Min Jiang,Zhenyong Zhang,Rong Wu,Jianing Miao,Caigang Liu,Song Gao

DOI: https://doi.org/10.3389/fonc.2022.793448

IF: 4.7

2022-04-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.641399.].

oncology
Dual Target Gene Therapy to EML4-ALK NSCLC by a Gold Nanoshell-Based System: Erratum

Siwen Li,Yuxi Liu,Yalan Rui,Liping Tang,Samuel Achilefu,Yueqing Gu

DOI: https://doi.org/10.7150/thno.43075

IF: 11.6

2020-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.24469.].
Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Yifeng Xia,Jingnan An,Jiaying Li,Wenxing Gu,Yifan Zhang,Songsong Zhao,Cenzhu Zhao,Yang Xu,Bin Li,Zhiyuan Zhong,Fenghua Meng

DOI: https://doi.org/10.1016/j.bioactmat.2023.08.011

IF: 18.9

2024-01-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.08.032.].
Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

DOI: https://doi.org/10.2147/IJN.S500182

2024-10-14

Abstract:[This corrects the article DOI: 10.2147/IJN.S448556.].
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong,Hui-Min Lei,Qian Liang,Ya-Bin Tang,Ye Zhou,Yang Wang,Shengzhe Zhang,Wen-Bin Li,Yunguang Tong,Guanglei Zhuang,Liang Zhang,Hong-Zhuan Chen,Liang Zhu,Ying Shen

DOI: https://doi.org/10.7150/thno.58558

IF: 11.6

2021-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.23177.].

medicine, research & experimental
Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment"

Hongye He,Feng Li,Rui Tang,Nianhong Wu,Ying Zhou,Yuting Cao,Can Wang,Li Wan,Yang Zhou,Hua Zhuang,Pan Li

DOI: https://doi.org/10.34133/bmr.0088

2024-10-07

Abstract:[This corrects the article DOI: 10.34133/bmr.0064.].
Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Zhiwen Fu,Jinmei Liu,Shijun Li,Chen Shi,Yu Zhang

DOI: https://doi.org/10.1016/j.eclinm.2023.101908

IF: 15.1

2023-01-01

EClinicalMedicine

Abstract:[This corrects the article DOI: 10.1016/j.eclinm.2023.101904.][This corrects the article DOI: 10.1016/j.eclinm.2022.101795.].
Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

Fangling Cheng,Po Zhang,Qungen Xiao,Youwei Li,Minhai Dong,Heping Wang,Dong Kuang,Yue He,Qiuhong Duan,Feng Mao,Baofeng Wang,Dongsheng Guo

DOI: https://doi.org/10.3389/fonc.2020.591112

2020-09-25

Abstract:[This corrects the article DOI: 10.3389/fonc.2019.00447.].
Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Jianlin Xu,Haitang Yang,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huiming Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1038/srep38270

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 36371; published online: 04 November 2016; updated: 01 December 2016

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Correction: Targeting Tumor Cell-Derived CCL2 As a Strategy to Overcome Bevacizumab Resistance in ETV5+ Colorectal Cancer.

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Dual Target Gene Therapy to EML4-ALK NSCLC by a Gold Nanoshell-Based System: Erratum

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment"

Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.